BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 18573339)

  • 1. Immunogenic anti-cancer chemotherapy as an emerging concept.
    Haynes NM; van der Most RG; Lake RA; Smyth MJ
    Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunological aspects of anticancer chemotherapy].
    Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
    Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.
    van der Most RG; Currie AJ; Robinson BW; Lake RA
    Cell Death Differ; 2008 Jan; 15(1):13-20. PubMed ID: 18007666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells and their role in cancer immunotherapy.
    Jalili A
    Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 'kiss of death' by dendritic cells to cancer cells.
    Chan CW; Housseau F
    Cell Death Differ; 2008 Jan; 15(1):58-69. PubMed ID: 17948029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic cancer cell death: a key-lock paradigm.
    Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
    Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer.
    Wesa AK; Storkus WJ
    Cell Death Differ; 2008 Jan; 15(1):51-7. PubMed ID: 17948028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene transfer approaches in cancer immunotherapy.
    Larin SS; Georgiev GP; Kiselev SL
    Gene Ther; 2004 Oct; 11 Suppl 1():S18-25. PubMed ID: 15454953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor stress, cell death and the ensuing immune response.
    Ullrich E; Bonmort M; Mignot G; Kroemer G; Zitvogel L
    Cell Death Differ; 2008 Jan; 15(1):21-8. PubMed ID: 17992190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity.
    Calderwood SK; Theriault JR; Gong J
    Eur J Immunol; 2005 Sep; 35(9):2518-27. PubMed ID: 16144035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve immunotherapy drugs that could cure cancers.
    Cheever MA
    Immunol Rev; 2008 Apr; 222():357-68. PubMed ID: 18364014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new era for innate immunity.
    Montero Vega MT
    Allergol Immunopathol (Madr); 2008; 36(3):164-75. PubMed ID: 18680705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate and adaptive immune pathways to tolerance.
    Thornton CA; Morgan G
    Nestle Nutr Workshop Ser Pediatr Program; 2009; 64():45-57; discussion 57-61, 251-7. PubMed ID: 19710514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.
    Radfar S; Wang Y; Khong HT
    J Immunol; 2009 Nov; 183(10):6800-7. PubMed ID: 19846868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma.
    McCoy MJ; Nowak AK; Lake RA
    Tissue Antigens; 2009 Jul; 74(1):1-10. PubMed ID: 19422663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characteristics of immunogenic cancer cell death.
    Tesniere A; Panaretakis T; Kepp O; Apetoh L; Ghiringhelli F; Zitvogel L; Kroemer G
    Cell Death Differ; 2008 Jan; 15(1):3-12. PubMed ID: 18007663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific and non-specific responses in host resistance to tumors.
    Baldwin RW
    Tokai J Exp Clin Med; 1983 Dec; 8(5-6):419-28. PubMed ID: 6398929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.